Key Summary Points {#FPar1}
==================

Respiratory viral infections represent one of the most feared complications in the hematological patient in terms of both clinical severity and mortality.Influenza (IFV) and parainfluenza viruses (PIV), respiratory syncytial virus (RSV), adenovirus (AdV), rhinovirus (RhV) and coronavirus (CoV) are the most relevant agents involved in respiratory infections.Respiratory infections in immunocompromised patients have an initial involvement of the upper respiratory tract; the feared progression to the lower respiratory tract is strictly related to clinical conditions of patients as well as several risk factors.Defining effective therapeutic and prophylactic strategies is challenging, especially considering the variability spectrum of onco-hematological patients and the variety of respiratory viruses involved.Although the scientific community recognizes the relevance of these infections, there is no uniform consensus on available clinical management options, diagnostic and therapeutic tools, and preventive and prophylaxis measures.

Background {#Sec1}
==========

Infections are among the most important complications in subjects affected by cancer and/or in recipients of hematopoietic stem cell transplantation (HSCT) and often endanger the life of the immunosuppressed patient \[[@CR1]\]. Infections affecting the respiratory system are particularly frequent in this population, and those involving the lower respiratory tract (LRTI) are often related to the highest severity and mortality \[[@CR1]\]. Among the various etiological agents, community-acquired respiratory viruses (CRVs) represent a relevant cause in terms of morbidity and mortality among patients with hematological malignancies \[[@CR2]\].

On one hand, the progress of therapeutic interventions has led to an increase in the survival and recovery of hematological patients; on the other, the wide use of chemotherapy and immunosuppressive treatments has further increased the infective risk for these patients \[[@CR3]\].

Although attempts have been made to standardize the clinical and therapeutic approach to infective complications in immunocompromised hematological patients, the clinical expression of infections is extremely variable. The continuous changes in the epidemiology of infections, clinical manifestations of hematological patients and available therapies imply a lack of an uniform consensus on the best management of infective complications and the need for continuous updates \[[@CR3]\]. Besides, the optimal approach to infective complications often needs to be personalized.

The reduced availability of easy and specific diagnostic methods has long hindered the feasibility of epidemiological studies on this issue; the advent of biomolecular tests has made it possible to obtain timely and accurate diagnosis of viral infections \[[@CR2]\].

The exponential increase in interest in community-acquired viruses has been related to a growing number of scientific papers evaluating their role in the field of respiratory diseases in immunosuppressed patients \[[@CR2]\].

From these premises, it is clear that infections in general still represent a frequent complication, and in some cases the main cause of death in these patients; it is therefore important to establish methods to prevent these problems \[[@CR4]\]. In this review we will deal with respiratory viral infections in pediatric and adult hematological patients, describing epidemiological aspects, available diagnostic tools, treatment options and preventive measures. This article is based on previously conducted studies and does not contain any studies with human participants or animals performed by any of the authors.

Respiratory Viral Infections in Hematological Patients {#Sec2}
======================================================

Main Viruses and Pathogenesis {#Sec3}
-----------------------------

Many relevant and well-known viral agents are involved in the onset of respiratory diseases in hematological patients such as influenza (Flu) and parainfluenza virus (PiV), respiratory syncytial virus (RSV), adenovirus (hAdV), rhinovirus (hRV) and coronavirus (CoV) as well as lesser known ones such as human metapneumovirus (hMPV) and bocavirus (hBoV) \[[@CR2]\].

Other very well known pathogens such as herpes viruses \[cytomegalovirus (CMV), Epstein-Barr virus (EBV), varicella-zoster virus (VZV), herpes simplex 1 and 2 (HSV1-2) and herpesvirus-6\] frequently cause serious diseases in these patients but rarely affect the respiratory system. These diseases can follow a first contact with the virus or a viral reactivation related to immunosuppressive conditions \[[@CR3], [@CR4]\].

RSV is a single-stranded RNA virus belonging to the *Paramyxoviridae* family. Its genome can code for 11 proteins, including G and F proteins, important in the initial stages of infection; these proteins allow the virus to bind and penetrate within the epithelial cells of the upper airways \[[@CR5]\].

The human influenza virus belongs to the *Orthomyxoviridae* family, and its genome is characterized by a single-stranded RNA segment. Its surface proteins, hemagglutinin (HA) and neuroaminidase (NA), play a fundamental role in the pathogenesis of infection and allow for the identification of different subtypes \[[@CR2], [@CR5]\]. Three influenza virus genera are identified (A, B, C); influenza A virus is divided into different subtypes on the basis of the antigenic drift and shift mechanisms, which lead to minor or major changes in the composition of HA and NA, respectively \[[@CR6]\].

Rhinoviruses (hRV) belong to the *Picornaviridae* family. They have a single-stranded RNA segment and are divided in three species (A, B and C) according to genomic and capsid characteristics.\[[@CR5], [@CR6]\]. To date, \> 100 serotypes are known \[[@CR5]\]; 90% of these use the same receptor protein to penetrate the epithelial cells (I-CAM 1) \[[@CR7]\].

Parainfluenza viruses (PiV) and metapneumovirus (hMPV) belong to the *Paramyxoviridae* family and have a single-stranded RNA segment. The PiV genome encodes six proteins: among these, hemagglutinin-neuraminidase (HN) and fusion protein F allow the virus to bind to the host cell and to merge with it. To date, five serotypes are known, which differ from each other from an epidemiological and clinical point of view.

hMPV, like RSV, binds to the host cell via a G protein and merges with it via an F protein; two hMPV subtypes are known (A and B, further divided into two subgroups: A1/A2, B1/B2) \[[@CR5]\].

Coronaviruses (CoV) are capsulated, single-stranded RNA viruses belonging to the *Coronaviridae* family. Although they are a common cause of colds in the general population, limited information is available in immunocompromised patients \[[@CR5]\].

Adenoviruses (hAdV) are double-stranded, non-capsulated DNA viruses consisting of \> 60 serotypes divided into 7 species or subgroups (A--G). The various serotypes can be associated with different clinical manifestations according to different receptor tropisms in different tissues \[[@CR6]\].

Bocavirus (hBoV) is a small DNA virus belonging to the *Parvoviridae* family \[[@CR6]\]. Currently, four hBoV variants are known: HBoV1, HBoV2, HBoV3 and HBoV4. HBoV1 was mainly isolated in LRTI, often associated with other pathogens, unlike the other three that generally cause gastroenteritis.

Respiratory viruses can be transmitted by direct contact and by inhalation of Flugge droplets or fomites. Capsulated viruses can resist in fomites for 2--72 h \[[@CR6]\].

The T cell-mediated immune response is fundamental to protecting humans from viral infections. As this mechanism may be lacking in patients who undergo stem cell transplantation or who undergo immunosuppressive therapies, hematological patients are particularly susceptible to viral infections and to related complications \[[@CR8]\].

Risk Factors {#Sec4}
------------

The clinical conditions of hematological patients, together with several risk factors, predispose patients to the onset of respiratory infections involving both the upper (URTI) and lower respiratory tract (LRTI).

In pediatric patients, a systematic review conducted in 2015 identified eight risk factors significantly associated with the development of LRTI infection in children: prematurity, low birth weight, male gender, having siblings, maternal smoking, history of atopy, lack of breastfeeding and crowding \[[@CR9]\].

Advanced age, lymphopenia and recent allogenic stem cell transplantation have been recognized as general risk factors for the development of RSV lower respiratory tract infection \[[@CR10]\]. In particular, HSCT patients may be at risk of CMV reactivation, an infection that can result in multi-organ involvement and in an increased risk of graft-versus-host disease (GVHD) \[[@CR9]\].

In candidates for hematopoietic stem cell transplantation, a positive anamnesis for smoking, conditioning regimen with total high-dose body irradiation and absolute lymphocyte count \< 100 mm^3^ are significantly related to a risk of progression \[[@CR11]\]. In addition, corticosteroid therapy administered at the onset of URTI is associated with a greater progression to LRTI \[[@CR10]\].

The following risk factors for symptomatic progression to LRTI are known for RSV and PiV infections: advanced age, history of smoking, allogeneic HSCT, myeloablative regimen, neutropenia, lymphocytopenia, non-correspondent or unrelated donor transplant, graft-versus-host disease (GVHD), pre-engraftment status or early post-transplant period, and systemic use of corticosteroids \[[@CR8]\].

The progression of influenza virus to LRTI implies lymphopenia, the use of steroids and the delayed start of antiviral therapy \[[@CR11]\].

In patients with coronavirus infection, the presence of co-pathogens such as RSV and host-related factors such as age \< 5 years and being immunocompromised are factors that can contribute to LRTI progression \[[@CR11]\].

Outline of Clinical Aspects {#Sec5}
---------------------------

The severity of respiratory infections in immunocompromised patients is greater than that observed in immunocompetent subjects, although the clinical picture is substantially similar.

Diseases caused by these viruses vary from URTIs, usually self-limiting, to LRTIs, which are potentially lethal. The clinical evolution depends, as already stated, on the condition of the patient as well as the intrinsic virulence of the virus.

At onset, reported symptoms are therefore unspecific and related to an initial involvement of the upper respiratory tract: cough, rhinorrhea, otitis media, wheezing, and sore throat with or without fever \[[@CR4], [@CR12]\].

Other less frequently observed symptoms are diarrhea or gastrointestinal symptoms and conjunctivitis \[[@CR9]\]. In other cases, as in influenza virus infection, the typical manifestations may be absent \[[@CR2]\]. Dyspnea, hypoxemia and possible lung infiltrates may appear on chest x-ray with progression to LRTI \[[@CR8]\]. Neutropenia is not a pivotal clinical fact but is rather a condition that predisposes patients to bacterial infections \[[@CR4]\].

Epidemiology {#Sec6}
------------

The estimated incidence of the above-mentioned respiratory viruses has a wide range due to the variability in screening and diagnostic methods as well as study design. In hematological and HSCT patients, the trend and seasonal peak roughly reflect the classic behavior of these viruses in the population, although there are possibilities for significant variations in terms of incidence and mortality year by year \[[@CR6]\].

Epidemic RSV outbreaks typically occur in winter like for influenza, except in tropical areas where the latter can occur throughout the year. Parainfluenza viruses generally spread all year round, with peaks in spring--summer, a period in which a greater number of hMPV cases are also observed \[[@CR2]\].

hRV, RSV, PiV, hAdV and hMPV are the most frequently isolated viruses in myeloma patients, who generally have the highest median age. Seasonal peaks have been observed in winter and spring, except for PiV, which peaks in summer \[[@CR13]\].

In pediatric subjects, hRV is the main cause of respiratory infection compared to RSV and PiV \[[@CR4], [@CR9], [@CR14]\]. Also in this category of patients, a prevalent seasonality in winter (31.5%) and spring (26.5%) has been observed \[[@CR9]\].

Marinelli et al. estimate that, in patients treated with autologous stem cell transplantation, hRV is the most common community-acquired virus (47%) followed by PiV (14.1%), influenza (11.2%), RSV (11.8%) and hMPV (8.8%) \[[@CR8]\]. Viruses that most frequently cause respiratory infections in the HSCT candidate patient include: RSV, AdV, influenza, PIV, hMPV, RhV, CoV and hBoV \[[@CR15]\].

Respiratory Syncytial Virus (RSV) {#Sec7}
---------------------------------

Respiratory syncytial virus is the most important causative agent of LRTI in infants and children worldwide \[[@CR16], [@CR17]\]. Many children develop a primary infection within the first 2 years of life, but despite this permanent immunity is not acquired \[[@CR18]\]. A Finnish study, evaluating serological IgG levels, showed that 37% of children had contracted an RSV infection in the first year of life, 68% within 2 years and 86% within 3 years of age. At least a third of these children then develop reinfection in subsequent years, confirming the fact that immunity in the first years of life is only partially protective \[[@CR19]\]. The incidence rate of RSV infection in adult and pediatric hematologic subjects ranges between 1 and 50% (Table [1](#Tab1){ref-type="table"}) \[[@CR6]\]. This value ranges between 1 and 12% taking into account only adults \[[@CR20]\] (Table [2](#Tab2){ref-type="table"}). Although the mortality rate for pneumonia in healthy children and adults is low (0.5%), this can reach 60% in immunocompromised untreated children and adults \[[@CR17]\].Table 1Incidence, mortality, preventive and therapeutic options against main respiratory infections in hematological patients. Modified from \[[@CR6], [@CR32]\]VirusIncidence (%)Mortality (%)Preventive optionsTherapeutic optionsRespiratory syncitial virus1--5011--47S, C, DPavilizumabRibavirin aerosolInfluenza1.3--408--28S, DSeasonal influenza immunizationPost-exposure prophylaxis with oseltamivirOseltamivirRhinovirus2--34\< 5--41S, DNDMetapneumovirus2--116--40S, CNDParainfluenza virus3--2710--50S, A, DRibavirinCidofovirBocavirus1--3Not reportedS, C, DNDAdenovirus1--3014--73S, C, DNDCoronavirus3--23\< 5--54S, C, DND*A* airborne precautions, *C* contact precautions, *D* droplet precautions, *S* standard precautionsTable 2Incidence of the most common respiratory virus infections in children and adults with hematological malignancyHematological patientsChildrenAdultsRespiratory syncytial virusHM--1--12% \[[@CR20]\]ALL14--31% \[[@CR22]\]--AML0.3--2.2% \[[@CR22]\]--Lymphoma----Myeloma--40--60% \[[@CR13]\]Other tumors8.7% \[[@CR23]\]--RhinovirusHM33.0% \[[@CR12]\]40% \[[@CR33]\]Leukemia33.9% \[[@CR12]\]--Other tumors31.8% \[[@CR12]\]--InfluenzaHM----ALL36--38% \[[@CR5], [@CR22]\]--Parainfluenza virusHM10% \[[@CR39]\]2--7% \[[@CR20]\]ALL18% \[[@CR22]\]--Human metapneumovirusHM4--7% \[[@CR37], [@CR38]\]7% \[[@CR38]\]ALL10% \[[@CR22]\]--*HM* hematological malignancy not otherwise specified, *ALL* acute lymphoid leukemia, *AML* acute myeloid leukemia

The impact of RSV on immunocompromised patients with myeloma following stem cell or solid organ transplantation is well known, being associated in 40--60% of cases with a progression from the upper to the lower respiratory tract \[[@CR13], [@CR21]\]. Mortality can reach 30% after developing pneumonia \[[@CR13]\].

Morbidity and mortality from this infection increase in premature babies, and in children with underlying heart disease or severe immunosuppression \[[@CR16]\]. A single-center study \[[@CR22]\] found that RSV was the second most common cause of respiratory viral infection accounting for 31% of all episodes of respiratory viral infections in children with acute lymphoblastic leukemia (ALL).

RSV infections occur in 0.3--2.2% of pediatric patients with acute myeloid leukemia, 14% of children with ALL \[[@CR22]\] and 8.7% of children with various malignant diseases \[[@CR23]\].

In a prospective study conducted in Athens on children with hematological malignancies (65% of cases) or solid tumors who had received chemotherapy or HSCT treatment, the viral genome was isolated in 38.4% of subjects with URTI or LRTI infections, both febrile and nonfebrile. RSV was the most frequently isolated virus (46% of cases) followed by parainfluenza virus and bocavirus, identified in approximately 13% of children. Approximately 40% of children tested positive for a viral agent had a diagnosis of ALL, 11% of AML and 1% of lymphoma, respectively \[[@CR1]\].

Influenza Virus (FLU) {#Sec8}
---------------------

The influenza virus is probably the most studied and known of the community-acquired viruses.

Several countries, including Germany, have carried out seroprevalence studies on their population with regard to influenza A and B viruses: a prevalence of antibody levels (IgG) against viruses A and B has been observed in 87% and 47% of 0--17-year-old subjects, respectively. In adulthood, the antibody prevalence is around 96% for virus A and 98% for B, with a decreasing trend for antibodies against virus A with aging. Vaccinated children have a significantly higher antibody level than unvaccinated ones \[[@CR24]\]. Differently, a cross-sectional study performed in the United Arab Emirates showed a seroprevalence in the pediatric population quite similar to the one observed in the German population for B virus, but significantly lower for A virus \[[@CR25]\].

Several monocentric studies have evaluated the global impact of epidemics on hematological patients: mortality appears to be similar to that of the general population although the durations of hospitalization and antiviral treatment appear be longer for hematological patients \[[@CR2]\].

A retrospective study, performed in two cancer centers in the USA and Mexico on hematological patients hospitalized for influenza symptoms between 2009 and 2014 (during the AH1N1 pandemic and post-pandemic period), highlighted that the mean age of the patients was 49 (range 1--88) years and that the majority of patients had leukemia (54%). Besides, 42% of hospitalized patients developed LRTI and 16% died within 2 months of diagnosis \[[@CR26]\].

Two prospective European surveys, probably considering only the most severe cases, estimated the mortality linked to the 2009 AH1N1 pandemic in HSCT patients to be 6.3% \[[@CR2]\]. The incidence of influenza in hematological and/or transplant patients varies, according to the study, from very low to medium; nonetheless, the aforementioned virus remains a significant cause of morbidity and mortality \[[@CR6]\] (Table [1](#Tab1){ref-type="table"}). Nichols et al. report that the incidence in HSCT patients ranges between 1 and 3% \[[@CR27]\].

Influenza is the most common virus in ALL pediatric patients, making up about 36% \[[@CR22]\] and 38% \[[@CR5]\] of respiratory infections.

Notaby, influenza is highly variable in terms of both genome (antigenic drift, shift and recombination) and virulence; this variability can have a significant impact in immunosuppressed individuals (due to treatment or transplant regimens), with an increased risk of complications and death \[[@CR28]\].

In patients with myeloma, influenza is the respiratory virus associated with the greatest morbidity and mortality, and their risk of developing influenza is approximately six times higher than in controls \[[@CR10]\].

The increase in mortality due to this infection is related to the onset of respiratory complications, bacterial super-infections or the need for mechanical ventilation \[[@CR5]\].

Disease progression to LRTI occurs in up to 35%, and mortality ranges between 15 and 28% in patients with pneumonia. Therefore, early treatment is recommended within 2 days after the onset of symptoms \[[@CR11]\].

Human Rhinovirus (hRV) {#Sec9}
----------------------

hRV circulates throughout the year and is the most common cause of URTI, being responsible for around 52--79% of cases of colds. The incidence of infection in hematological patients is estimated between 2 and 34% \[[@CR6]\]. Although it causes a benign disease in immunocompetent patients, its role in terms of morbidity and mortality in at-risk subjects has only recently been highlighted \[[@CR2]\].

In children with hematological malignancies and/or HSCT, hRV was found in 23--62% of URTI \[[@CR29]--[@CR32]\] and 65% of LRTI \[[@CR14]\]. In this last work, the mean age of children was 6.9 years, and half of the patients affected by a respiratory virus had a diagnosis of leukemia or lymphoma (LL). hRV was the most detected virus in all the patients recruited in the study (hematological, with solid tumor or post-HSCT). In patients affected by leukemia or lymphoma and by a viral infection, hRV was detected in 65% of URTI and 59% of LRTI, while in children the virus represented 77% of URTI and 50% of LRTI in the post-HSCT period \[[@CR14]\].

The estimated mortality rate ranges between 5 and 41%, also according to host factors \[[@CR6]\].

A retrospective study showed that hRV was the most frequently isolated pathogen (33% of cases) in respiratory infections in pediatric cancer patients \[33.9% in acute lymphoblastic leukemia (ALL) and acute myeloid leukemia (AML) and 31.8% in solid tumors\] \[[@CR12]\].

A study carried out in adult patients with hematological malignancies showed that hRV was by far the most frequently identified pathogen (in about 40% of symptomatic patients); in detail, 32% of the total patients with hRV (110) were affected by ALL or myelodysplastic syndrome (MDS), 19% by chronic leukemia, and 49% by lymphoma, multiple myeloma (MM) or other. In addition, 45% of these patients were also HSCT recipients \[[@CR33]\].

In HSCT patients, hRV was identified as the second most frequent cause of idiopathic pneumonia (12% of the detected pathogens) \[[@CR2]\]. Fisher et al. showed that hRV was the most common pathogen detected in pediatric patients who underwent HSCT, followed by PiV and RSV \[[@CR34]\].

A retrospective study showed that around 40% of HSCT patients with documented hRV infection developed pneumonia and 60% of them had co-infections \[[@CR35]\].

Viruses belonging to this family represent the community-acquired pathogens most frequently involved in respiratory symptoms in HSCT candidates \[[@CR11]\].

The hRV incidence in immunocompromised children undergoing chemotherapy has been found to be up to 22.3% on the 100th day of treatment \[[@CR36]\], and hRV is by far the most common respiratory pathogen isolated in immunocompromised children undergoing chemotherapy treatment \[[@CR16]\].

Human Metapneumovirus (hMPV) {#Sec10}
----------------------------

Human metapneumovirus is a major cause of infection in children worldwide \[[@CR37]\]. Since it was discovered, several international studies have highlighted how primary infection occurs before 5 years of age and that all children are potentially infected at 10 years of life. Additionally, a number of reinfections may occur in subsequent years \[[@CR2]\]. To date, we know that this pathogen can be responsible for acute respiratory pictures not only in pediatric patients, but also in elderly and immunosuppressed subjects.

A systematic review evaluating data from 17 studies on hematological patients, HSCT patients or a combination of both revealed a total incidence of hMPV infection to 5% (range 0--40%). The incidence observed in hematological patients (7%) does not differ from that found in patients receiving stem cell transplantation. On the contrary, the incidence observed in adult patients was higher (7%) than in pediatric patients (4%). In studies in which patients with URTI and LRTI were taken into account, mortality was around 6% (range 0--17%); however, it was significantly higher in patients with LRTI (approximately 27%) \[[@CR38]\]. Hakim et al. showed a 10% incidence in patients with ALL \[[@CR22]\].

In the study conducted by Fontana and Strasfeld considering hematological and HSCT patients, an LRTI incidence between 2 and 11% was estimated \[[@CR6]\].

Another more recent review highlighted that 7% of all children with cancer who developed a respiratory infection were positive for hMPV. Of this 7%, about 1% died; 2.3% of pediatric patients who received a transplant and were hMPV positive died as well \[[@CR37]\].

Other studies confirm that immunocompromised children have a higher risk of developing LRTI as well as a higher risk of ICU (intensive care unit) admission and increased mortality \[[@CR11]\].

Although hMPV generally has a self-limiting course in the general population, severe disease and fatal outcomes have been reported, especially in HSCT patients; notably, co-morbidities make establishing the clear cause of the fatal outcome difficult \[[@CR2]\]. Compared to other viruses, hMPV infection has been found in most patients but its role in causing symptoms does not seem very crucial; nonetheless, it is not a negligible infection \[[@CR11]\].

Parainfluenza Virus (PiV) {#Sec11}
-------------------------

PiV is the second most frequently isolated virus as the causative agent of respiratory infections in pediatric hematological patients \[[@CR39]\]; according to a 2016 review, ALL is the hematological neoplasm most frequently associated with this virus. For adults this figure is not available \[[@CR40]\]. Fontana and Strasfeld estimate that its incidence varies between 3 and 27% in patients with hematological malignancy and/or HSCT \[[@CR6]\]. In adults, PiV incidence ranges between 2 and 7% \[[@CR20]\].

According to Shah et al., the incidence in HSCT patients (4%) is significantly higher than in hematological patients (2%). Mortality is estimated between 10 and 50% \[[@CR6]\] and can reach 17% in patients with pneumonia \[[@CR2]\]. However, no statistically significant differences between HSCT and hematological patients in terms of mortality have been highlighted \[[@CR40]\]. Common risk factors were found to be age (\< 2 years) and the development of LRTI.

An American study carried out in 2011 by Srinivasan et al. in pediatric patients showed that PiV caused 10% of viral respiratory infections and that PiV 3 caused most cases. PiV infections were more frequent in patients with ALL rather than in patients diagnosed with AML or lymphoma. No patients died \[[@CR39]\].

In 20--40% of patients suffering from URTI, the infection evolves in LRTI within, on average, 78 days. PiV-related mortality is approximately 10%, but increases to 27% if the infection progresses to LRTI \[[@CR11]\].

Citomegalovirus (CMV) {#Sec12}
---------------------

CMV is an opportunistic pathogen, occasionally associated with LRTI and pneumonia, not being considered a specific respiratory virus \[[@CR11]\].

The incidence of CMV infection in transplant patients was examined in a Chinese study. Of the total of patients (68) who underwent an allogeneic transplant, CMV infection was identified in 29% of cases, while a co-infection with RSV occurred in 26.5%. The average duration of CMV infection was 60 days versus 21 days of RSV infection. Of the 18 CMV/RSV co-infections, 11 developed severe pneumonia (68% of cases), while the same happened in only 31% of those who had single CMV or RSV infection. Five HSTC patients (approximately 7%) died of severe pneumonia \[[@CR17]\].

Seropositivity for CMV or reactivation of the same virus was documented in HSCT patients; this has been related to a greater risk of a severe clinical course and mortality \[[@CR8]\].

Bocavirus (hBoV) {#Sec13}
----------------

hBoV has been identified in samples of respiratory secretions, saliva, feces and blood in immunocompetent children. Sero-epidemiological studies showed a 90% seropositivity within 5 years of life \[[@CR15]\].

Bocavirus (hBoV) has been associated with 2--19% of all URTI and LRTI worldwide. The virus has also been found in patients with hematological malignancies or HSCT; however, it is difficult to establish its real impact in terms of morbidity and mortality because of the high frequency of co-infections \[[@CR2]\]; estimated incidence ranges between 1 and 3% \[[@CR6]\]. A prospective study carried out on children diagnosed with cancer showed that hBoV was present in 8% of viral respiratory infections and in 19% of LRTI. In the latter, 57% of cases were related to a co-infection with other viruses \[[@CR14]\].

Adenovirus (hAdV) {#Sec14}
-----------------

hAdV infections in HSCT recipients and in other severely immunocompromised hosts may be the consequence of new contact with the virus or the reactivation of endogenous infections \[[@CR6]\]. In immunocompromised and HSCT pediatric recipients, hAdV is associated with severe complications and mortality. hAdV infections are less common in adult patients (incidence range: 1--30%) \[[@CR6], [@CR11]\].

The range of hAdV-associated clinical manifestations is very wide, and URTI and LRTI are frequently caused by subgroups A, B and C. The incidence is generally higher in the pediatric population \[[@CR6]\].

A study of adult HSTC recipients reported an infection rate of 2.5%. Pneumonia occurred in 24% of cases, being the most common cause of hAdV-associated death \[[@CR11]\].

Coronavirus (CoV) {#Sec15}
-----------------

These viruses can circulate throughout the year, with a peak in winter. Thanks to having an animal reservoir, to their ability to infect also humans and to quickly transmit from human to human, they are recognized as very relevant pathogens of the new century \[[@CR2]\]. In contrast to the low incidence of bronchitis and pneumonia in healthy children, severe clinical pictures have been mainly described in immunocompromised patients \[[@CR11]\]. A cumulative incidence of 11%, 100 days after transplantation, has been shown in HSCT patients \[[@CR36]\]. According to the study by Fontana and Strasfeld \[[@CR6]\], the estimated incidence values range between 3 and 23% (Table [1](#Tab1){ref-type="table"}). Given the frequency of co-infection with other viruses, the cause of death is often difficult to identify \[[@CR5]\]. Recent studies also suggest that mortality may be comparable to that of influenza, RSV and parainfluenza virus \[[@CR2]\].

Diagnostic Tools {#Sec16}
================

It is not possible to reach a definite diagnosis considering only clinical manifestations; laboratory confirmation is strictly required, given that different respiratory viral infections could often have similar/overlapping clinical manifestations. Reaching a definite diagnosis is fundamental to prevent serious complications related to these infections \[[@CR41]\].

For diagnostic purposes, culture tests, considered the gold standard, immunoassays (ELISA), direct immunofluorescence (IF) and molecular tests (PCR) are currently used. The sensitivity of any diagnostic test is strictly related to the type of sample and site of sampling. For upper respiratory tract infections, nasopharyngeal washes or aspirates or nasopharyngeal swabs, preferable to pharyngeal swabs only, are recommended \[[@CR42]\]. In case of LRTI, tracheal aspiration or direct bronchoalveolar lavage (BAL) are recommended; the latter technique is highly sensitive but not always feasible in clinically debilitated patients \[[@CR43]\]. However, an observational retrospective study conducted in immunocompromised patients with viral lung disease showed that the results of PCR tests performed on nasopharyngeal samples are comparable to those performed on BAL \[[@CR44]\]. The involvement of the lower respiratory tract can be further confirmed or excluded by x-ray and computerized axial tomography (CAT) \[[@CR43]\].

The direct immunofluorescence antigen test is a quick and inexpensive diagnostic method with variable sensitivity (range 50--93%) \[[@CR45]\]; however, its use does not exclude the need for infection control measures pending the results obtained by PCR \[[@CR46]\].

The culture test is considered the gold standard for the diagnosis of these infections; however, it has a significant limitation, requiring a long time to obtain a result. Due to its high sensitivity and specificity as well as its speed, real-time polymerase chain reaction (PCR) is currently the preferred diagnostic method \[[@CR5], [@CR47]\].

These methods are quick, extremely sensitive and specific and have the additional advantage of being quantitative, offering the potential for multiplex testing platforms. This is a fundamental characteristic taking into account the \"multi-etiological\" nature of viral respiratory infections in the patients under study \[[@CR48]\]. This feature is important for monitoring infections and for discriminating the pathogenic role of a given virus in the case of co-infections or of a low viral load. Besides, the evaluation of the viral load allows identifying patients at high risk or candidates for more urgent therapy \[[@CR11]\]. These techniques tend to be more expensive than other direct and indirect diagnostic methods \[[@CR5]\].

Therapeutic Options {#Sec17}
===================

As a general rule, respiratory infection management consists of providing the patient with supportive care and, where possible, carrying out antiviral therapy \[[@CR6]\].

For influenza, its increased resistance to M2 inhibitors (amantadine and rimantadine) has made the neuraminidase inhibitor oseltamivir the most used anti-influenza therapeutic option in immunosuppressed patients \[[@CR11]\]. In patients with myeloma, oseltamivir reduces the risk of developing pneumonia as well as relapses \[[@CR13]\], while a delay in the initiation of its use can lead to the onset of complications such as progression to LRTI and death in HSCT recipients \[[@CR11]\]. According to the Public Health England guidance, the use of oral oseltamivir, 75 mg twice daily for 15 days, is recommended for patients \> 13 years of age as the first-line treatment, provided that the risk of drug resistance is low. An early start of treatment, 48 h after the onset of symptoms in uncomplicated cases and for a minimum of 5 days, is appropriate. As an alternative therapeutic regimen, or in forms complicated by involvement of the lower respiratory tract, the use of zanamivir, in intravenous or nebulized formulation, has been approved \[[@CR43]\].

Additional corticosteroid therapy is useful to reduce the inflammatory state and to prevent progression to LRTI; however, corticosteroids worsen the state of immunosuppression, predisposing patients to a prolongation of viral spreading \[[@CR2]\].

Regarding RSV infection, ribavirin-based therapy has been associated with a significant reduction in the progression from URTI to LRTI \[[@CR5]\]. Ribavirin has been proven effective in hindering the progression from URTI to LRTI (from 45 to 16%) and in reducing mortality (from 70 to 35%) in onco-hematological patients \[[@CR5]\]. The lack of ribavirin aerosol therapy has increased the risk of mortality in patients with HSCT \[[@CR49]\]; ribavirin aerosol is the only approved treatment for severe RSV-related LRTI in infants with underlying conditions such as prematurity, cardiopulmonary disease or immunosuppression \[[@CR5]\]. In patients with myeloma, routine treatment of RSV infection is not recommended \[[@CR13]\]. Ribavirin therapy is recommended in patients with leukemia and patients with HSCT at high risk of complications \[[@CR5]\].

The co-administration of ribavirin with intravenous immunoglobulins (IVIG), with specific anti-RSV immunoglobulins or with pavilizumab is currently still poorly defined. However, there is a general consensus that a late start of the therapy, when pulmonary symptoms have already established, compromises its effectiveness \[[@CR48]\]. For PiV, the use of antiviral agents such as ribavirin, intravenous immunoglobulins or a combination of these drugs does not have a significant impact on reducing the length of hospital stay, the duration of symptoms and mortality. Very few new antiviral drugs have shown promising results for the treatment of PIV infection in this type of patient \[[@CR29]\].

A retrospective study showed that neither intravenous administration of immunoglobulins nor the use of aerosol ribavirin are useful strategies for the effective reduction of the viral load.

Therapy is mainly supportive, and since corticosteroid therapy has been shown to be a risk factor for progression towards LRTI, a valid therapeutic approach could be a reduction in the steroid dosage \[[@CR43]\].

There is currently no specific recommended treatment for rhinovirus \[[@CR6], [@CR11]\], bocavirus \[[@CR11]\], metapneumovirus \[[@CR5]\] and coronavirus \[[@CR5], [@CR6], [@CR11]\].

Most patients with hMPV do not require therapy, as its efficacy in reducing the risk of progression of the infection has not been demonstrated; as asymptomatic spreading of the virus may persist, serial control by means of PCR is required \[[@CR43]\].

Promising results following the use of IVIG and ribavirin have been obtained in vitro; however, these data have not been confirmed or validated in vivo \[[@CR48]\].

Even for adenovirus there is no formally indicated antiviral treatment.

Several studies have been conducted with promising results in vitro regarding the use of antiviral drugs such as cidofovir, ganciclovir and other antiretroviral drugs (zalzitabine, alovudine, stavudine) but there are not as many validations in vivo \[[@CR48]\]. Cidofovir has been shown to reduce mortality, but it is related to kidney and ocular toxicity \[[@CR6]\].

Prevention and Prophylaxis {#Sec18}
==========================

Defining effective therapeutic and prophylactic strategies for this type of infections is challenging, especially considering the spectrum variability of onco-hematological patients and the variety of respiratory viruses involved. Early diagnosis and early supportive care of high-risk patients allow reducing the progression of the pathology from the upper to lower respiratory tract \[[@CR5]\].

Given the high morbidity and mortality as well as the lack of vaccines and of specific antiviral therapy for most of these infections, preventive measures remain the best approach to reducing the spread of viral infections in myeloma patients and in subjects with HSCT. It is also important to raise awareness among patients and healthcare professionals about the impact of these viruses on immunocompromised patients \[[@CR29]\].

The reduction of transmission of viral respiratory infections is potentially feasible through the adoption of a series of measures; the most effective ones include hand hygiene, screening of visiting family members for respiratory symptoms, education of healthcare staff and isolation of the patients with respiratory symptoms \[[@CR28], [@CR43]\].

The high cost of antiviral therapy and lack of a clear efficacy in these patients highlights the need for effective vaccines against these respiratory viruses. According to the 2013 Infectious Diseases Society of America Guidelines, an intramuscular influenza vaccine is recommended for all immunocompromised patients and HSCT recipients aged 6 months or older \[[@CR30]\]. It is also desirable to extend the annual immunization to family members and healthcare personnel in contact with the patient \[[@CR43]\]. Even in patients with multiple myeloma, an effective preventive strategy to reduce the risk of influenza is represented by the seasonal influenza immunization. Although patients with multiple myeloma are known to not have high levels of specific anti-influenza antibodies compared to healthy subjects, the vaccine reduces the risk of URTI and the number of hospitalizations. Strategies such as immunization before transplantation or a double-dose schedule improve the immune response \[[@CR13]\].

Neuramidase inhibitors should be prophylactically administered to all immunocompromised patients with a close contact with proven or suspected cases of infection. For influenza, the infective period is estimated from 1 day before to 7 days after the development of the symptoms, and post-exposure chemoprophylaxis should last up to 7 days after the last known exposure \[[@CR4]\].

Regarding RSV, the prophylactic use of palivizumab (monoclonal antibody against RSV) in young children undergoing HSCT was recommended in the 2009 international guidelines to prevent infective complications; however, the lack of clear evidences on its efficacy has limited the application of this measure \[[@CR29]\].

The use of aerosol ribavirin and pavilizumab as preventive strategies in patients with URTI evolving in LRTI is still debated, especially in lymphopenic patients \[[@CR48]\].

Regarding PiV, the real impact of ribavirin and of experimental anti-viral agents such as DAS 181 on mortality or on progression to pneumonia has yet to be determined \[[@CR5]\].

Lastly, immunotherapy for RSV and influenza has so far given promising results \[[@CR5]\].

As previously stated, infections caused by influenza virus have been successfully treated with neuramidase inhibitors (oseltamivir); however, its efficacy for influenza pneumonia has not been established, and antiviral resistance frequently occurs in immunocompromised patients.

Retrospective studies demonstrate positive outcomes with ribavirin (alone or in combination with immunomodulators) for the treatment of RSV infections in patients with hematological disease and HSCT. However, no prospective clinical studies have yet been conducted to demonstrate its clear efficacy \[[@CR5]\].

Future studies should focus on strategies to identify patients at high risk of developing these infections and to determine the efficacy of available and new antiviral drugs.

Phase 1 studies are currently in progress to evaluate the safety and immunogenicity of a vaccine against PIV; phase 2 studies evaluating the efficacy of the new agent DAS-181 against PIV in immunocompromised patients are ongoing \[[@CR13]\].

Conclusions {#Sec19}
===========

Hematological patients are by definition at risk subjects. Therefore, although respiratory viruses often cause self-limiting infections in the population, diagnosing these infections quickly in this group of patients is important for several reasons.

First, we need to avoid complications, even fatal ones, related to these infections \[[@CR4]\].

Considering that the new treatments actually guarantee an increase in survival, a further positive effect could be achieved by strengthening the supportive treatments to combat these infections; this would allow obtaining better tolerability of the aggressive therapeutic regimens these patients undergo \[[@CR2]\]. The major limitation of this review is that reported results stem from few cases, often with limited significance. However, it is confirmed that respiratory viral infections continue to cause disease in both the pre- and post-transplant period; in the event of an onset in the pre-transplant period, it is advisable to delay the transplant, but there are no clear indications in this regard. Deferral of take in charge, although it could be the most reasonable choice, is not always feasible, especially in the presence of conditions such as important lymphopenia or persistent aplasia \[[@CR50]\].

In children, where the viral shedding is longer, delayed treatment should be strongly considered, even in asymptomatic subjects \[[@CR11]\].

The positive outcome of the transplant itself is strongly influenced by a possible progression of the disease from the upper to the lower respiratory tract.

As mentioned, it would be useful to act on those risk factors that predispose patients to this progression. Lymphopenia appears to be the main factor implicated in this progression \[[@CR11]\], but in preventive terms it is desirable to intervene also because of a number of other factors. It is known that the progression of the pathology is also favored by the presence of several bacterial or fungal co-infections, often transmitted by visitors and family members who have not been properly informed about the preventive measures to be taken.

In conclusion, control strategies should be implemented in the hospital environment given the limited efficacy of available therapies especially in immunocompromised subjects; preventive measures should be adopted and implemented as well \[[@CR4]\].
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